A
T
P
About
Team
Portfolio
ATP R&D
News
Locations
Contact
Filter by
Year
All
2024
2023
2022
Archive
All
Company
All
ATP
Aethon Therapeutics
Ascidian Therapeutics
Aulos Bioscience
Braeburn
Chinook Therapeutics
Deep Apple Therapeutics
Galvanize Therapeutics
Initial Therapeutics
Marengo Therapeutics
Nereid Therapeutics
Nine Square Therapeutics
Red Queen Therapeutics
Replicate Bioscience
All
Dec 03, 2024
Red Queen Therapeutics Announces Expanded Licensing Agreement, Progress in Its Pan-Influenza Program
Nov 27, 2024
Aulos Bioscience Doses First Patient in Phase 2 Cohort Evaluating the Combination of Avelumab and AU-007 for the Treatment of Non-Small Cell Lung Cancer
Nov 09, 2024
Marengo Presents Promising First-in-Human Safety, Tolerability and Clinical Activity Data for its Lead Program, Invikafusp Alfa (STAR0602), at the 2024 SITC Annual Meeting
Nov 07, 2024
Strong Evidence of AU-007’s Anti-Tumor Activity in Advanced Solid Tumor Cancers Presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 30, 2024
Marengo to Unveil First-in-Human Data for its Novel, Selective Dual T Cell Agonist, Invikafusp Alfa (STAR0602) in a Late Breaking Oral Presentation at SITC 2024 Annual Meeting
Oct 23, 2024
Aulos Bioscience Presents Phase 2 Dose Selection Data for Novel IL-2 Therapeutic Antibody, AU-007, at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Oct 09, 2024
Aulos Bioscience Announces Presentation Detailing Phase 2 Dose Selection for AU-007 in Solid Tumor Treatment at 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics
Oct 04, 2024
Aulos Bioscience to Present Promising Phase 2 Data for Novel IL-2 Therapeutic Antibody, AU-007, at 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 30, 2024
Braeburn Debuts Inspiring Docuseries Celebrating Advocates Uplifting Communities to Combat the Opioid Crisis
Sep 27, 2024
Ascidian Therapeutics Named to 2024 "Endpoints 11" List of Most Promising Biotechs
Sep 13, 2024
Marengo Therapeutics Announces Clinical Study Collaboration with Gilead Sciences to Evaluate Invikafusp alfa (STAR0602) and Trodelvy® in both Metastatic TNBC and Metastatic HR+/HER2- Breast Cancers
Aug 21, 2024
Replicate Bioscience to Participate in Upcoming Investor and Scientific Conferences
Aug 06, 2024
Apple Tree Partners Launches Red Queen Therapeutics to Bring Potentially Lifesaving Treatments to People at Greatest Risk from Viral Infections
Aug 06, 2024
Galvanize Therapeutics Completes Enrollment in Clinical Trial Evaluating Aliya® Pulsed Electric Field (PEF) System for Late-Stage Non-Small Cell Lung Cancer and Metastasis to the Lung
Jul 30, 2024
Nine Square Therapeutics Appoints James B. Summers, Ph.D., to Board of Directors and Scientific Advisory Board
Jul 02, 2024
Galvanize Appoints Executive Chairman and New Oncology-Focused Director to the Board of Directors
Jun 18, 2024
Ascidian Therapeutics Enters Collaboration with Roche for Discovery and Development of RNA Exon Editing Therapeutics Targeting Neurological Diseases
Jun 07, 2024
Ipsen and Marengo Therapeutics Announce Second Strategic Partnership to Advance Precision T Cell Engagers from Marengo’s Tri-STAR Platform
May 28, 2024
Galvanize Receives FDA Clearance for the INUMI Flex Endoscopic Needle, Expanding its Aliya® Pulsed Electric Field (PEF) Portfolio for Soft Tissue Ablation
May 23, 2024
Aulos Bioscience Provides Positive Interim Phase 1/2 Data From AU-007 at 2024 ASCO Annual Meeting
May 15, 2024
Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck KGaA, Darmstadt, Germany To Study Combination of Bavencio® With AU-007
May 11, 2024
Replicate Bioscience Presents Positive Data from Phase 1 Trial and Preclinical Data with Novel Self-Replicating RNA at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Apr 24, 2024
Aulos Bioscience to Present Updated Phase 1/2 Clinical Trial Results for Novel IL-2 Therapeutic AU-007 in Advanced Solid Tumor Cancers at 2024 ASCO Annual Meeting
Apr 22, 2024
Replicate Bioscience Announces Oral Presentations at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
Apr 18, 2024
Initial Therapeutics Names Peter DiLaura as CEO
Apr 04, 2024
Aethon Therapeutics Announces Collaboration with Revolution Medicines to Discover and Develop Novel Aethon Antibody Programs
Apr 02, 2024
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen
Mar 01, 2024
Replicate Bioscience to Participate in Upcoming Investor and Scientific Conferences
Feb 14, 2024
Replicate Bioscience Announces Positive Initial Clinical Results for its Next Generation srRNA Technology
Jan 29, 2024
Ascidian Therapeutics Announces First-Ever IND for an RNA Exon Editor as FDA Approves Trial Plan and Fast Tracks ACDN-01 in Stargardt Disease and Other ABCA4 Retinopathies
Jan 25, 2024
First Patient Dosed in Phase 2 Portion of Aulos Bioscience’s Phase 1/2 Clinical Trial for AU-007, a Computationally Designed IL-2 Antibody for Solid Tumor Cancers
Jan 05, 2024
Novel Compound Protects Against Infection by Virus that Causes COVID-19, Preliminary Studies Show
Dec 18, 2023
Aulos Bioscience Advances AU-007 to Phase 2 Portion of Phase 1/2 Study Evaluating Computationally Designed IL-2 Antibody for Treatment of Solid Tumors
Dec 14, 2023
Apple Tree Partners Unveils Deep Apple Therapeutics to Dramatically Accelerate Drug Discovery with Structure-Based, Ultra-Large Library Virtual Screening and Deep Learning Models
Dec 07, 2023
Marengo Therapeutics and Kings College London Announce Publication in Science Advances Highlighting the Discovery of a New Approach to T Cell Activation
Dec 06, 2023
Marengo Therapeutics Announces Publication Describing STAR0602, a Novel, TCR-Targeting Cancer Immunotherapy, in Science Translational Medicine
Nov 13, 2023
Nereid Therapeutics Appoints Michael Kauffman as CEO
Nov 08, 2023
Ascidian Therapeutics Raises $40 Million in Series A Extension Financing from Apple Tree Partners and Appoints Michael Ehlers as Interim CEO
Nov 06, 2023
Galvanize Therapeutics Announces Promising Data on the Aliya™ Pulsed Electric Field (PEF) System in Early-Stage Non-Small Cell Lung Cancer
Nov 03, 2023
New Phase 1 Dose Escalation Data Show Well-Tolerated Safety Profile and Anti-Tumor Activity for Aulos Bioscience’s AU-007 at Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 14, 2023
New Phase 1 Dose Escalation Cohorts Data for Aulos Bioscience’s AU-007 Show Favorable Pharmacodynamic Effects at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Oct 04, 2023
Aulos Bioscience to Present Encouraging Pharmacodynamic Data for AU-007 From Phase 1 Dose Escalation Cohorts at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 27, 2023
Aulos Bioscience Announces Presentation of Updated Safety and Efficacy Data From First-in-Human Phase 1/2 Clinical Trial of AU-007 at 38th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 20, 2023
Galvanize Therapeutics Begins U.S. Clinical Study Using Aliya™ Pulsed Electric Field (PEF) for Stage IV Non-Small Cell Lung Cancer or Metastasis to the Lung
Sep 12, 2023
Nine Square Therapeutics Awarded $4.5 Million Grant from The Michael J. Fox Foundation to Advance Development of Novel Parkin Activators
Sep 12, 2023
Replicate Bioscience Initiates a Phase 1 Trial of its Next-Generation srRNA Vaccine
Sep 05, 2023
BRIXADI® (buprenorphine) Extended-Release Injection for Subcutaneous Use (CIII) is Now Available in the U.S. for the Treatment of Moderate to Severe Opioid Use Disorder
Aug 01, 2023
Aulos Bioscience Raises $20 Million in Series A Extension Financing From Apple Tree Partners
Jul 11, 2023
Apple Tree Partners Recruits Noted Biotech Entrepreneur and Computer-Aided Drug Design Pioneer Matthew P. Jacobson, Ph.D., as New Venture Partner
Jul 10, 2023
Replicate Bioscience Appoints Rachael Lester as Chief Business Officer
Jun 19, 2023
Galvanize Therapeutics Completes Enrollment in Pivotal Trial of RheOx® System for Chronic Bronchitis
Jun 12, 2023
Chinook Therapeutics Enters into Agreement to be Acquired by Novartis AG
May 30, 2023
Galvanize Announces License Agreement and Partnership with Energenx Medical for its Technologies in China
May 25, 2023
Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells
May 23, 2023
FDA News Release: FDA Approves New Buprenorphine Treatment Option for Opioid Use Disorder
May 23, 2023
Braeburn's BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection (CIII) Receives FDA Approval for Moderate to Severe Opioid Use Disorder
May 09, 2023
Ascidian Therapeutics to Present New Data From Its Lead Program Targeting ABCA4 Retinopathies at the ASGCT 2023 Annual Meeting
May 01, 2023
With $75 Million from Apple Tree Partners, Initial Therapeutics Launches to Create a New Kind of Drug Designed to Stop the Formation of Difficult-to-Drug Protein Targets
Apr 19, 2023
Replicate Bioscience Presents Preclinical srRNA Data at the American Association for Cancer Research Annual Meeting 2023
Apr 18, 2023
Ascidian Therapeutics to Present Data From Its Lead Program Targeting ABCA4 Retinopathies at the Retinal Cell and Gene Therapy Innovation Summit and ARVO 2023 Annual Meeting
Apr 11, 2023
Ascidian Therapeutics Announces Three Key Development Team Appointments as It Advances Its Lead Program Toward the Clinic
Mar 22, 2023
Marengo Therapeutics to Present a Late-Breaking Abstract at AACR Annual Meeting 2023 Highlighting Broad Application of its Novel TCR Vβ Targeting Platform
Mar 20, 2023
Ascidian Therapeutics Appoints Jay A. Barth, M.D., as Chief Medical Officer
Mar 14, 2023
Replicate Bioscience Shares New Preclinical srRNA Data at American Association for Cancer Research Annual Meeting 2023
Mar 07, 2023
New Interventional Oncology Data Show Potential for Aliya™ Pulsed Electric Field (PEF) System in Treatment of Solid Tumors
Mar 01, 2023
Marengo Therapeutics Appoints Kevin Chin, MD, MS as Chief Medical Officer
Mar 01, 2023
Galvanize Therapeutics Announces First Human Use of QuickShot: A Novel Contact-Sensing, Large Area, Focal Pulsed Electric Field Mapping and Ablation Catheter
Feb 17, 2023
Gene editing: DNA versus RNA (Drug Discovery News)
Feb 01, 2023
First U.S. Patient Dosed in Aulos Bioscience’s Phase 1/2 Clinical Trial of AU-007, a Novel IL-2 Therapeutic for the Treatment of Solid Tumors
Jan 27, 2023
Marengo Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial of its Novel TCR Vβ Directed Antibody-Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy
Jan 09, 2023
ATP and NYU Langone Health Launch Aethon Therapeutics to Eradicate Drug-Resistant Cancer Cells
Jan 04, 2023
Ascidian Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 23, 2022
Braeburn Applauds Passage of Significant Advancements in the Treatment of Opioid Use Disorder
Dec 08, 2022
FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Nov 10, 2022
Marengo Therapeutics Presents Preclinical Data Supporting Clinical Investigation of its Lead Asset, STAR0602, at the 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 10, 2022
Aulos Bioscience Presents Initial Data From First-in-Human Phase 1/2 Clinical Trial of Computationally Designed Antibody AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 10, 2022
Galvanize Therapeutics Presents Clinical Data Using Pulsed Electric Field (PEF) Energy for Non-Small Cell Lung Cancer
Oct 31, 2022
Aulos Bioscience Announces FDA Clearance of IND Application for AU-007, a Novel Immunotherapy for the Treatment of Solid Tumors
Oct 28, 2022
Marengo Therapeutics Presents Preclinical Proof-of Concept Data for STAR0602, a First-in-class Selective T cell Activator, at the 34th EORTC-NCI-AACR Symposium 2022
Oct 17, 2022
New Biotechnology Combines Targeted and Immune Therapies to Kill Treatment-resistant Cancer Cells
Oct 12, 2022
Marengo Therapeutics to Give Plenary Oral Presentation at 34th EORTC-NCI-AACR (ENA) Symposium on Lead Program, STAR0602 and Present Additional Data at the SITC Conference Featuring its Vβ-Targeted Selective T Cell Ac
Oct 12, 2022
Ascidian Therapeutics Launches to Rewrite RNA
Oct 11, 2022
Aulos Bioscience to Present Initial Safety Data From First-in-Human Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 at 37th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Sep 22, 2022
Nereid Therapeutics Co-Founder Clifford Brangwynne Awarded 2023 Breakthrough Prize in Life Sciences
Sep 20, 2022
How 3 companies merged and raised $100M to treat range of diseases by pulsing cells (San Francisco Business Times)
Sep 16, 2022
Marengo Therapeutics Advances First-In-Class Selective T cell Activator, STAR0602, into Human Trials in Solid Tumors and Enters Cooperative Research and Development Agreement with the National Cancer Institute
Sep 15, 2022
Galvanize Therapeutics Announces Merger to Create the Premier Pulsed Electric Field Therapy Company and Completion of $100 Million Series B Financing
Sep 13, 2022
Nine Square Therapeutics Appoints John Hood to Board of Directors
Aug 01, 2022
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates from Marengo’s STAR Platform into the Clinic
Jul 26, 2022
Precision NanoSystems and Replicate Bioscience in Licensing Deal to Scale Up Genomic Medicines
Jul 12, 2022
Replicate Bioscience Expands Leadership Team, Appointing Zelanna Goldberg, M.D., as Chief Medical Officer and Mohit Trikha, Ph.D., to Board of Directors
Jul 12, 2022
Marengo Therapeutics Announces Formation of Scientific Advisory Board to Advance the Company's Development of Novel Therapeutics for Precision Immuno-Oncology
Jun 15, 2022
Marengo Therapeutics Expands Executive Leadership Team with Svetlana Makhni Joining as Chief Financial Officer
Jun 09, 2022
Curia and Replicate Bioscience Enter Strategic Collaboration to Create Groundbreaking Development Platform for Self-Replicating RNA (srRNA)
May 26, 2022
Aulos Bioscience Presents Poster on Phase 1/2 Clinical Trial of Computationally Designed IL-2 Antibody AU-007 at 2022 ASCO Annual Meeting
May 09, 2022
Marengo Therapeutics Appoints Ke Liu, MD, PhD, and Bruce Chabner, MD, to Key Leadership Roles, Strengthening Marengo's Development Team and Supporting Translation to the Clinic
May 05, 2022
Aulos Bioscience Initiates Phase 1/2 Clinical Trial of IL-2 Therapeutic AU-007 for the Treatment of Solid Tumors
Apr 27, 2022
Aulos Bioscience Announces Presentation on First-in-Human Phase 1/2 Clinical Trial of Novel IL-2 Therapeutic AU-007 at 2022 ASCO Annual Meeting
Mar 21, 2022
Aulos Bioscience Announces Preclinical Data Demonstrating Ability of Novel IL-2 Therapeutic AU-007 to Eliminate Solid Tumors
Mar 09, 2022
Marengo Therapeutics to Participate in Investor, Scientific, Industry Conferences
Mar 07, 2022
Apple Tree Partners Donates to Humanitarian Relief Efforts in Ukraine
Mar 03, 2022
ATP Statement on War in Ukraine
Feb 23, 2022
Aulos Bioscience Receives HREC Approval to Initiate First-in-Human Clinical Trial Evaluating Anti-Tumor Activity of Novel IL-2 Therapeutic AU-007
Feb 08, 2022
Gala Therapeutics Announces First Commercial Cases Worldwide with RheOx® System for Chronic Bronchitis
Jan 11, 2022
Nine Square Therapeutics Appoints Robert Paul as CEO
Jan 06, 2022
Marengo Therapeutics to Present at Annual J.P. Morgan Health Care Conference
Nov 12, 2021
Aulos Bioscience Presents Preclinical Data Demonstrating Anti-Tumor Activity of AU-007, a Novel IL-2 Therapeutic, at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Nov 08, 2021
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
Nov 01, 2021
Nereid Therapeutics Announces Scientific Advisory Board Membership
Oct 25, 2021
Nereid Therapeutics Announces Appointments of Laura Forese and Rupert Vessey to Its Board of Directors
Oct 21, 2021
ATP Names Raj Chopra, FRCP, FRCPath, FRSB, Ph.D., as Head of Oncology
Oct 05, 2021
Aulos Bioscience to Present New Preclinical Data on Computationally Evolved IL-2 Human Antibody AU-007 at 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Oct 04, 2021
ATP Founds New Center for CRISPR Target Discovery in Collaboration with Innovative Genomics Institute (IGI) and Jennifer Doudna
Sep 20, 2021
Galaxy Medical Enrolls First Patients in SPACE-AF Study
Sep 08, 2021
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Aug 31, 2021
Data from Multiple Studies Show Positive Outcomes with Gala Therapeutics' RheOx™ System for Chronic Bronchitis
Jul 28, 2021
Galaxy Medical Releases ECLIPSE-AF Remapping Data at Stanford Biodesign Retreat and Update on System Interoperability
Jun 26, 2021
FDA Accepts Braeburn’s New Drug Application Resubmission for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Jun 15, 2021
Braeburn Resubmits New Drug Application for BRIXADI™ (buprenorphine) Extended-Release Subcutaneous Injection for Moderate to Severe Opioid Use Disorder
Jun 14, 2021
Jim Vasselli, M.D., Joins Aulos Bioscience as Chief Medical Officer
May 20, 2021
Gala Therapeutics Announces First Patients Enrolled in Pivotal Trial of RheOx™ System for Chronic Bronchitis
May 17, 2021
Aulos Bioscience Appoints Leo Redmond as Chief Financial Officer
May 14, 2021
Nine Square: Taking Aim at Organelle Function in Movement Disorders with Computation and Imaging (BioCentury Emerging Company Profile)
May 12, 2021
Galaxy Medical and Japan Lifeline Enter Distribution Agreement For Novel Pulsed Electric Field Focal Ablation Catheter
May 08, 2021
Breathing Life into Britain’s Life-Sciences Industry (The Economist)
Mar 30, 2021
Mace Rothenberg, M.D., Joins Aulos Bioscience Board of Directors
Mar 16, 2021
Galaxy Medical Receives $18 Million from ATP to Advance Development of Its Novel Pulsed Electric Field Ablation Therapy for Cardiac Arrhythmias
Mar 15, 2021
Aulos Bioscience Appoints Aron Knickerbocker as CEO
Mar 02, 2021
Doug Godshall to Chair Gala Therapeutics Board of Directors
Feb 22, 2021
Gala Therapeutics Receives FDA Approval to Commence Pivotal Trial to Evaluate the RheOx™ System for Chronic Bronchitis
Jan 08, 2021
ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
No articles match your selection. Try again.